9-epi-mitomycin D | 79026-43-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 9-epi-mitomycin D
• 英文别名: mitomycin D；9-Epimitomycin D；[(4S,6S,7R,8S)-11-amino-7-hydroxy-5,12-dimethyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate
• CAS: 79026-43-0
• 化学式: C₁₅H₁₈N₄O₅
• 分子量: 334.332
• InChiKey: JHIATKDBEBOOCO-NTMSUYENSA-N

物化性质

• 熔点：
  >210 °C (decomp)
• 沸点：
  601.7±55.0 °C(Predicted)
• 密度：
  1?+-.0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  139
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  9-epi-mitomycin D 在 sodium hydroxide 、 sodium hydride 作用下， 反应 6.42h， 生成 N-甲基丝裂霉素A
  参考文献：
  名称：

  Synthesis of 9-epi-mitomycin B: the first inversion of the C-9 stereochemistry in mitomycin B

  摘要：

  DOI：

  10.1021/jo00286a021
• 作为产物：
  描述：

  9-epi-10-O-decarbamoyl-10-O-(phenoxycarbonyl)mitomycin D 在 氨 作用下， 以 氯仿 为溶剂， 反应 1.5h， 以94.2%的产率得到9-epi-mitomycin D
  参考文献：
  名称：

  Synthesis of 9-epi-mitomycin B: the first inversion of the C-9 stereochemistry in mitomycin B

  摘要：

  DOI：

  10.1021/jo00286a021

文献信息

• Anti-cancer compounds
  申请人：——

  公开号：US20020019404A1

  公开（公告）日：2002-02-14

  The present invention relates to 2-substituted 4-heteroaryl-pyrimidines, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders such as cancer, leukaemia, psoriasis and the like.

  本发明涉及2-取代的4-杂环芳基嘧啶、其制备、含有它们的药物组合物以及它们作为细胞周期依赖性激酶（CDKs）抑制剂的用途，因此可用于治疗癌症、白血病、牛皮癣等增生性疾病。
• [EN] PROCESS FOR THE PREPARATION OF GUANIDINO SUBSTITUTED BI-AND POLYPHENYLS THAT ARE SUITABLE AS SMALL MOLECULE CARRIERS<br/>[FR] PROCÉDÉ DE PRÉPARATION DE BI- ET POLYPHÉNYLES GUANIDINO SUBSTITUÉS CONSTITUANT DE BONS VECTEURS DE PETITES MOLÉCULES
  申请人：UCL BUSINESS PLC

  公开号：WO2009027679A1

  公开（公告）日：2009-03-05

  A process for the production of a compound of formula (I), or a pharmaceutically acceptable salt thereof, Formula (I) which process comprises:(a) coupling a compound of formula (II) to a compound of formula (III) to form a compound of formula (IV).

  生产化合物(I)或其药用盐的方法，该方法包括：(a)将化合物(II)偶联到化合物(III)以形成化合物(IV)的步骤。
• [EN] BI- OR TETRA-GUANIDINO-BIPHENYL COMPOUNDS AS SMALL MOLECULE CARRIERS<br/>[FR] COMPOSES BI-GUANIDINO-BIPHENYLE OU TETRA-GUANIDINO-BIPHENYLE SERVANT DE PETITES MOLECULES PORTEUSES
  申请人：UNIV LONDON

  公开号：WO2005123676A1

  公开（公告）日：2005-12-29

  The invention relates to compounds of formula: I, or pharmaceutically acceptable a salts thereof, I wherein X1 X2 and X3 are each independently where Y is an alkylene, alkenylene or alkynylene group, each of which may be optionally substituted with one or more substituents selected from alkyl, halo, CF3, OH, alkoxy, NH2, CN, NO2 and COOH; W is absent or is O, S or NH; Rl, R2, R3 and R4 are each independently selected from H, alkyl, aryl and a protecting group Pl; R7, R8 and R9 are each independently selected from H, alkyl, halo, CF3, OH, alkoxy, NH2, CN, NO2 and COOH; q and r are each independently 1, 2, 3 or 4; q' and r' are each independently 0, 1, 2 or 3, where q + q' and r + r' each equal 4; p is 1, 2, 3, 4 or 5, and p' is 0, 1, 2, 3 or 4, where p + p' is 5; n is 0, 1, 2, 3....6; L is (Z)mNR5R6 where Z is a hydrocarbyl group and m is 0 or 1; where R5 and R6 are each independently H, CO(CH2)jQ1 or C=S(NH)(CH2)kQ2 where j and k are each independently 0, 1, 2, 3, 4 or 5, and Q1 and Q2 are each independently selected from COOH, a chromophore or R5, R6 and the nitrogen to which they are attached together form.

  该发明涉及以下结构的化合物：I，或其药学上可接受的盐，其中X1、X2和X3各自独立，其中Y是一个烷基，烯烃或炔烃基团，每个基团可能选择性地被一个或多个从烷基、卤素、CF3、羟基、烷氧基、NH2、CN、NO2和COOH中选择的取代基所取代；W不存在或是O、S或NH；R1、R2、R3和R4各自独立地选择自H、烷基、芳基和一个保护基Pl；R7、R8和R9各自独立地选择自H、烷基、卤素、CF3、羟基、烷氧基、NH2、CN、NO2和COOH；q和r各自独立地为1、2、3或4；q'和r'各自独立地为0、1、2或3，其中q + q'和r + r'分别等于4；p为1、2、3、4或5，p'为0、1、2、3或4，其中p + p'为5；n为0、1、2、3....6；L为(Z)mNR5R6，其中Z为一个烃基团，m为0或1；其中R5和R6各自独立地为H、CO(CH2)jQ1或C=S(NH)(CH2)kQ2，其中j和k各自独立地为0、1、2、3、4或5，Q1和Q2各自独立地选择自COOH、一个色团或R5、R6和它们所连接的氮共同形成。
• [EN] VITAMIN-MITOMYCIN CONJUGATES<br/>[FR] CONJUGUES VITAMINE-MITOMYCINE
  申请人：ENDOCYTE INC

  公开号：WO2003097647A1

  公开（公告）日：2003-11-27

  The invention relates to vitamin-mitomycin conjugates, to a method of using the conjugates to selectively eliminate a population of pathogenic cells in a host animal harboring the pathogenic cells, and to a method of preparation of the conjugates. The conjugate is of general formula B-L-X wherein the group B is a vitamin, or an analog or a derivative thereof, that binds to a surface accessible vitamin receptor that is uniquely expressed, overexpressed, or preferentially expressed by a population of pathogenic cells, wherein the group L comprises a cleavable linker, and wherein the group X comprises a mitomycin compound, or an analog or a derivative thereof. An additional therapeutic agent, such as a chemotherapeutic agent, can be administered in combination with the conjugate.

  本发明涉及维生素-丝裂霉素偶联物，以及使用该偶联物选择性消除寄生细胞群体的方法，以及该偶联物的制备方法。该偶联物的一般式为B-L-X，其中B基团是维生素或其类似物或衍生物，可结合到表面可接触的维生素受体，该受体仅由寄生细胞群体表达、过表达或偏好表达，L基团包括可裂解的连接剂，X基团包括丝裂霉素化合物或其类似物或衍生物。可以与该偶联物一起给予其他治疗剂，例如化疗剂。
• Herbal composition PHY906 and its use in chemotherapy
  申请人：Cheng Yung-Chi

  公开号：US20050196473A1

  公开（公告）日：2005-09-08

  This invention provides herbal compositions useful for increasing the therapeutic index of drugs, including those used in the treatment of disease, especially viral infections and neoplasms of cancer. This invention provides methods useful for improving the quality of life of an individual undergoing chemotherapy. Furthermore, this invention improves the treatment of disease by increasing the therapeutic index of chemotherapy drugs by administering the herbal composition PHY906 to a person undergoing such chemotherapy.

  该发明提供了草药组合物，可用于增加药物的治疗指数，包括用于治疗疾病，特别是病毒感染和癌症新生物的药物。该发明提供了有用的方法，用于改善接受化疗的个体的生活质量。此外，该发明通过向正在接受化疗的人口中给予草药组合物PHY906，提高了化疗药物的治疗指数，从而改善了疾病的治疗。